Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free BEAM Stock Alerts

Beam Therapeutics (BEAM) Financials

Beam Therapeutics logo
$29.46 +0.17 (+0.58%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Beam Therapeutics

Annual Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -91 -196 -371 -289 -133 -377 -80
Consolidated Net Income / (Loss)		 -78 -195 -371 -289 -133 -377 -80
Net Income / (Loss) Continuing Operations		 -78 -195 -371 -289 -133 -377 -80
Total Pre-Tax Income 		-78 -195 -371 -260 -131 -377 -80
Total Operating Income		 -75 -133 -392 -338 -176 -416 -384
Total Gross Profit		 0.02 0.02 52 61 378 64 140
Total Revenue		 0.02 0.02 52 61 378 64 140
Operating Revenue		 0.02 0.02 52 61 378 64 140
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 75 133 444 399 554 479 523
Selling, General & Admin Expense		 21 30 57 88 117 112 114
Research & Development Expense		 55 103 387 312 437 368 410
Total Other Income / (Expense), net		 -3.17 -62 22 78 45 39 304
Interest Expense		 -2.23 -1.05 0.01 -15 -47 -49 -44
Interest & Investment Income		 - - - - - - 255
Other Income / (Expense), net		 -5.40 -63 22 63 -1.35 -10 4.82
Income Tax Expense		 - 0.00 0.00 3.41 1.37 0.04 0.00
Basic Earnings per Share		 ($14.05) ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Weighted Average Basic Shares Outstanding		 6.48M 46.73M 64.23M 70.02M 77.15M 82.31M 98.91M
Diluted Earnings per Share		 ($14.05) ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Weighted Average Diluted Shares Outstanding		 6.48M 46.73M 64.23M 70.02M 77.15M 82.31M 98.91M
Weighted Average Basic & Diluted Shares Outstanding		 6.48M 46.73M 68.73M 72.40M 81.66M 83.69M 101.86M

Quarterly Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 143 -99 -91 -97 -90 -108 -102 -113 244 -94 -123
Consolidated Net Income / (Loss)		 143 -99 -91 -97 -90 -108 -102 -113 244 -94 -123
Net Income / (Loss) Continuing Operations		 143 -99 -91 -97 -90 -108 -102 -113 244 -94 -123
Total Pre-Tax Income 		48 -99 -91 -97 -189 -108 -102 -113 244 -94 -123
Total Operating Income		 133 -104 -105 -107 -100 -119 -120 -127 -17 -107 -127
Total Gross Profit		 316 7.41 12 14 30 7.47 8.47 9.70 114 32 0.49
Total Revenue		 316 7.41 12 14 30 7.47 8.47 9.70 114 32 0.49
Operating Revenue		 316 7.41 12 14 30 7.47 8.47 9.70 114 32 0.49
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 183 112 117 121 130 127 129 137 131 139 127
Selling, General & Admin Expense		 43 27 30 27 29 28 27 27 32 34 32
Research & Development Expense		 140 85 87 94 101 99 102 110 99 105 95
Total Other Income / (Expense), net		 11 5.46 14 9.84 9.68 11 18 14 262 13 3.88
Interest Expense		 -12 -12 -14 -12 -11 -9.86 -12 -11 -11 -9.87 -7.49
Interest & Investment Income		 - - - - - - 0.00 - - - 0.46
Other Income / (Expense), net		 -0.76 -6.39 -0.31 -2.26 -1.25 1.12 5.69 3.18 -4.10 3.03 -4.07
Basic Earnings per Share		 $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.23) ($1.00) ($1.10) $2.53 ($0.91) ($1.18)
Weighted Average Basic Shares Outstanding		 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M 104.33M
Diluted Earnings per Share		 $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.23) ($1.00) ($1.10) $2.53 ($0.91) ($1.18)
Weighted Average Diluted Shares Outstanding		 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M 104.33M
Weighted Average Basic & Diluted Shares Outstanding		 81.66M 82.31M 82.42M 82.81M 83.69M 100.56M 101.16M 101.47M 101.86M 102.88M 103.29M

Annual Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -97 126 396 -327 199 -155 12
Net Cash From Operating Activities		 -72 -96 -66 23 -149 -347 -345
Net Cash From Continuing Operating Activities		 -72 -96 -66 23 -149 -347 -345
Net Income / (Loss) Continuing Operations		 -78 -195 -371 -289 -133 -377 -80
Consolidated Net Income / (Loss)		 -78 -195 -371 -289 -133 -377 -80
Depreciation Expense		 3.50 4.74 7.45 14 20 22 22
Amortization Expense		 -0.92 0.12 -0.08 -0.98 -30 -23 -16
Non-Cash Adjustments To Reconcile Net Income		 12 92 -109 378 109 129 -140
Changes in Operating Assets and Liabilities, net		 -8.17 2.20 406 -80 -116 -99 -131
Net Cash From Investing Activities		 -67 -100 -294 -461 72 185 -121
Net Cash From Continuing Investing Activities		 -66 -99 -294 -461 72 185 -121
Purchase of Property, Plant & Equipment		 -13 -16 -47 -49 -34 -8.95 -15
Acquisitions		 - - - - 0.00 0.00 -0.08
Purchase of Investments		 -130 -282 -777 -1,617 -984 -486 -1,210
Divestitures		 0.00 0.00 0.62 0.00 0.00 0.00 255
Sale and/or Maturity of Investments		 76 199 529 1,205 1,090 680 848
Net Cash From Financing Activities		 41 322 756 112 276 7.74 478
Net Cash From Continuing Financing Activities		 41 322 756 112 276 7.74 478
Repayment of Debt		 -0.46 -1.57 - -2.29 -2.25 -0.49 0.00
Repurchase of Common Equity		 -2.52 -2.06 -8.82 -0.19 0.00 0.00 0.00
Issuance of Common Equity		 0.00 320 757 111 273 2.62 473
Other Financing Activities, net		 0.19 3.16 7.51 2.73 6.13 5.60 4.77
Cash Interest Paid		 0.19 0.56 0.57 0.38 0.16 0.03 0.00

Quarterly Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 267 -150 4.62 -62 53 244 -246 -14 27 -6.64 -68
Net Cash From Operating Activities		 135 -100 -83 -88 -76 -104 -76 -81 -83 -129 -66
Net Cash From Continuing Operating Activities		 135 -100 -83 -88 -76 -104 -76 -81 -83 -129 -66
Net Income / (Loss) Continuing Operations		 143 -99 -91 -97 -90 -108 -102 -113 244 -94 -123
Consolidated Net Income / (Loss)		 143 -99 -91 -97 -90 -108 -102 -113 244 -94 -123
Depreciation Expense		 5.36 5.43 5.58 5.48 5.44 5.53 5.54 5.56 5.67 5.61 5.41
Amortization Expense		 2.17 -6.58 -5.93 -5.62 5.03 -3.85 -4.62 -4.23 -3.26 -2.73 -2.54
Non-Cash Adjustments To Reconcile Net Income		 7.81 35 33 31 21 25 15 45 -229 19 25
Changes in Operating Assets and Liabilities, net		 -23 -35 -25 -22 -17 -22 10 -15 -101 -56 28
Net Cash From Investing Activities		 98 -53 87 25 126 -125 -170 66 108 25 -9.88
Net Cash From Continuing Investing Activities		 98 -53 87 25 126 -125 -170 66 108 25 -9.88
Purchase of Property, Plant & Equipment		 -3.59 -2.44 -1.96 -1.58 -2.97 -3.07 -3.14 -5.01 -3.73 -2.23 -2.41
Purchase of Investments		 -53 -195 -134 -157 - -339 -334 -176 -361 -154 -181
Sale and/or Maturity of Investments		 155 144 224 183 129 217 167 246 218 181 173
Net Cash From Financing Activities		 34 2.90 0.13 1.26 3.44 473 1.11 1.68 1.89 97 7.52
Net Cash From Continuing Financing Activities		 34 2.90 0.13 1.26 3.44 473 1.11 1.68 1.89 97 7.52
Other Financing Activities, net		 0.75 1.68 0.24 0.24 3.45 0.72 1.76 0.41 1.89 2.03 7.52
Cash Interest Paid		 0.02 0.01 0.01 0.01 - 0.00 - - - 0.00 2.57

Annual Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 156 452 1,474 1,342 1,460 1,104 1,481
Total Current Assets		 95 308 1,273 1,093 1,211 878 1,269
Cash & Equivalents		 37 162 560 233 436 282 295
Short-Term Investments		 55 138 406 845 754 569 950
Prepaid Expenses		 2.70 8.65 7.36 15 21 27 23
Plant, Property, & Equipment, net		 24 39 84 116 125 111 105
Total Noncurrent Assets		 37 105 117 133 124 114 108
Other Noncurrent Operating Assets		 37 105 117 133 124 114 108
Total Liabilities & Shareholders' Equity		 156 452 1,474 1,342 1,460 1,104 1,481
Total Liabilities		 55 206 648 608 478 370 243
Total Current Liabilities		 29 102 213 224 206 182 97
Short-Term Debt		 - - - - - 0.00 2.71
Accounts Payable		 7.85 6.31 7.47 9.03 1.62 3.87 10
Accrued Expenses		 7.85 18 68 50 112 47 55
Current Deferred Revenue		 - 0.02 86 136 69 109 6.66
Other Current Liabilities		 13 78 52 29 24 22 22
Total Noncurrent Liabilities		 26 104 434 385 273 188 146
Long-Term Debt		 - - - - - - 0.00
Noncurrent Deferred Revenue		 - 0.39 262 202 110 33 0.00
Other Noncurrent Operating Liabilities		 22 103 172 182 163 155 146
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -201 246 827 733 981 734 1,238
Total Preferred & Common Equity		 -201 246 827 733 981 734 1,238
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -201 246 827 733 981 734 1,238
Common Stock		 1.92 643 1,595 1,793 2,171 2,299 2,878
Retained Earnings		 -203 -398 -768 -1,057 -1,190 -1,567 -1,641
Accumulated Other Comprehensive Income / (Loss)		 0.02 -0.01 -0.05 -2.43 0.60 0.68 1.11

Quarterly Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 1,332 1,354 1,291 1,360 1,261 1,171 1,467 1,391 1,311 1,481 1,386
Total Current Assets		 1,083 1,095 1,040 1,122 1,029 946 1,248 1,175 1,099 1,267 1,179
Cash & Equivalents		 250 226 169 288 293 230 528 282 268 288 220
Short-Term Investments		 810 847 846 807 715 696 692 868 807 923 933
Prepaid Expenses		 24 22 24 27 21 20 28 25 24 55 26
Plant, Property, & Equipment, net		 122 128 128 121 117 114 110 109 108 101 98
Total Noncurrent Assets		 127 131 123 117 114 112 110 107 104 113 110
Other Noncurrent Operating Assets		 127 131 123 117 114 112 110 107 104 113 110
Total Liabilities & Shareholders' Equity		 1,332 1,354 1,291 1,360 1,261 1,171 1,467 1,391 1,311 1,481 1,386
Total Liabilities		 571 542 512 446 407 380 344 344 345 316 319
Total Current Liabilities		 220 210 220 187 177 166 142 174 183 75 81
Short-Term Debt		 - - - - - - - - 1.19 2.70 2.77
Accounts Payable		 14 6.89 3.18 2.79 4.43 3.81 7.70 11 9.55 12 13
Accrued Expenses		 38 38 42 86 67 52 30 41 42 39 40
Current Deferred Revenue		 143 139 153 72 85 89 85 106 110 0.30 0.00
Other Current Liabilities		 25 26 22 26 21 21 18 17 19 20 25
Total Noncurrent Liabilities		 351 333 291 259 230 214 202 170 163 242 238
Long-Term Debt		 - - - - - - - - - 100 100
Noncurrent Deferred Revenue		 172 156 125 100 75 58 49 20 10 0.00 0.00
Other Noncurrent Operating Liabilities		 179 177 167 160 154 156 153 150 152 142 138
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 762 812 779 913 854 791 1,123 1,047 966 1,164 1,067
Total Preferred & Common Equity		 762 812 779 913 854 791 1,123 1,047 966 1,164 1,067
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 762 812 779 913 854 791 1,123 1,047 966 1,164 1,067
Common Stock		 1,916 2,050 2,114 2,203 2,235 2,266 2,799 2,825 2,856 2,901 2,928
Retained Earnings		 -1,154 -1,237 -1,333 -1,289 -1,380 -1,476 -1,676 -1,778 -1,891 -1,736 -1,858
Accumulated Other Comprehensive Income / (Loss)		 -0.77 -2.02 -2.02 -0.92 -1.11 1.76 0.16 0.01 0.79 -1.07 -2.19

Annual Metrics And Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 33.33% 215,916.67% 17.51% 520.01% -83.18% 120.01%
EBITDA Growth		 0.00% -144.69% -90.39% 27.79% 32.12% -134.19% 12.68%
EBIT Growth		 0.00% -142.87% -89.44% 25.67% 35.44% -139.43% 11.02%
NOPAT Growth		 0.00% -76.65% -195.62% 13.76% 47.86% -135.47% 7.67%
Net Income Growth		 0.00% -148.44% -90.47% 22.00% 54.16% -184.28% 78.77%
EPS Growth		 0.00% 70.18% -37.71% 28.42% 58.35% -166.28% 82.31%
Operating Cash Flow Growth		 0.00% -32.97% 30.78% 133.99% -762.29% -132.75% 0.62%
Free Cash Flow Firm Growth		 0.00% 0.00% -650.28% 83.58% -732.64% -47.22% 0.16%
Invested Capital Growth		 0.00% -500.58% -156.72% -148.12% 39.49% 43.80% 96.47%
Revenue Q/Q Growth		 0.00% 0.00% 6,538.16% -33.75% 363.14% -81.83% 150.88%
EBITDA Q/Q Growth		 0.00% -53.80% 8.09% 8.54% 51.06% -112.68% 16.14%
EBIT Q/Q Growth		 0.00% -52.47% 7.66% 6.71% 49.89% -121.29% 17.39%
NOPAT Q/Q Growth		 0.00% -12.19% -6.13% -8.15% 55.69% -127.49% 17.71%
Net Income Q/Q Growth		 0.00% -53.25% 7.66% 8.36% 57.75% -162.37% 80.71%
EPS Q/Q Growth		 0.00% 39.36% 14.90% 5.28% 58.75% -189.87% 81.72%
Operating Cash Flow Q/Q Growth		 0.00% -7.28% 28.28% -75.92% 57.79% -155.69% -2.05%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -21.08% -154.84% 38.53% -66.23% -8.09%
Invested Capital Q/Q Growth		 0.00% -2,417.92% -33.40% 9.32% 11.83% 12.83% 96.16%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -433,172.22% -794,958.33% -700.67% -430.58% -47.14% -656.46% -266.59%
Operating Margin		 -417,522.22% -553,166.67% -757.01% -555.61% -46.73% -654.25% -274.57%
EBIT Margin		 -447,522.22% -815,179.17% -714.89% -452.19% -47.08% -670.36% -271.12%
Profit (Net Income) Margin		 -435,144.44% -810,800.00% -714.91% -474.54% -35.09% -593.13% -57.24%
Tax Burden Percent		 100.00% 100.00% 100.00% 111.11% 101.04% 100.01% 100.00%
Interest Burden Percent		 97.23% 99.46% 100.00% 94.45% 73.75% 88.47% 21.11%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -389.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -360.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 311.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.59% -112.32% -69.13% -37.06% -15.46% -43.94% -8.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -51.60% -64.38% -38.48% -19.56% -12.70% -33.22% -29.31%
Return on Assets (ROA)		 -50.18% -64.03% -38.49% -20.53% -9.46% -29.39% -6.19%
Return on Common Equity (ROCE)		 154.58% -14.41% -69.13% -37.06% -15.46% -43.94% -8.11%
Return on Equity Simple (ROE_SIMPLE)		 38.95% -79.24% -44.83% -39.41% -13.50% -51.36% 0.00%
Net Operating Profit after Tax (NOPAT)		 -53 -93 -275 -237 -124 -291 -269
NOPAT Margin		 -292,265.56% -387,216.67% -529.91% -388.93% -32.71% -457.98% -192.20%
Net Nonoperating Expense Percent (NNEP)		 -29.41% -52.52% -15.16% -5.10% -0.79% -8.41% 18.02%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -32.30% -12.59% -39.66% -21.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 114,183.33% 123,354.17% 110.37% 144.13% 30.93% 175.58% 81.45%
R&D to Revenue		 303,438.89% 429,912.50% 746.64% 511.48% 115.80% 578.67% 293.12%
Operating Expenses to Revenue		 417,622.22% 553,266.67% 857.01% 655.61% 146.73% 754.25% 374.57%
Earnings before Interest and Taxes (EBIT)		 -81 -196 -371 -275 -178 -426 -379
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -191 -363 -262 -178 -417 -373
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 19.27 6.57 3.76 2.26 2.80 2.27
Price to Tangible Book Value (P/TBV)		 0.00 19.27 6.57 3.76 2.26 2.80 2.27
Price to Revenue (P/Rev)		 10,000.00 197,180.98 104.73 45.24 5.87 32.33 20.13
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 29.21 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 21,922.89 184,694.69 86.11 27.54 2.72 18.94 11.24
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 74.48 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.87 -1.12 -1.18 -1.31 -1.32 -1.19 -1.06
Leverage Ratio		 1.55 1.75 1.80 1.81 1.63 1.49 1.31
Compound Leverage Factor		 1.50 1.74 1.80 1.70 1.20 1.32 0.28
Debt to Total Capital		 4.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22%
Long-Term Debt to Total Capital		 4.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 286.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -190.88% 100.00% 100.00% 100.00% 100.00% 100.00% 99.78%
Debt to EBITDA		 -0.06 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to EBITDA		 1.12 0.00 0.00 0.00 0.00 0.00 3.34
Long-Term Debt to EBITDA		 -0.06 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.08 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to NOPAT		 1.66 0.00 0.00 0.00 0.00 0.00 4.63
Long-Term Debt to NOPAT		 -0.08 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.06 11.66 4.37 1.76 2.32 0.88 5.60
Noncontrolling Interest Sharing Ratio		 299.22% 87.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 3.24 3.01 5.96 4.89 5.89 4.82 13.09
Quick Ratio		 3.15 2.93 4.52 4.82 5.79 4.67 12.85
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -190 -31 -260 -382 -382
Operating Cash Flow to CapEx		 -575.20% -585.32% -141.57% 46.02% -442.30% -3,881.58% -2,308.99%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -21,102.94 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -7,363.11 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -12,564.33 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.05 0.04 0.27 0.05 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.84 0.61 3.14 0.54 1.29
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 14 -54 -139 -345 -209 -117 -4.14
Invested Capital Turnover		 0.00 0.00 -0.54 -0.25 -1.37 -0.39 -2.30
Increase / (Decrease) in Invested Capital		 0.00 -68 -85 -206 136 91 113
Enterprise Value (EV)		 395 4,433 4,464 1,678 1,029 1,203 1,570
Market Capitalization		 180 4,732 5,430 2,756 2,219 2,054 2,813
Book Value per Share		 ($31.04) $4.24 $12.13 $10.41 $12.04 $8.86 $12.20
Tangible Book Value per Share		 ($31.04) $4.24 $12.13 $10.41 $12.04 $8.86 $12.20
Total Capital		 105 246 827 733 981 734 1,241
Total Debt		 4.41 0.00 0.00 0.00 0.00 0.00 2.71
Total Long-Term Debt		 4.41 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -87 -300 -966 -1,078 -1,190 -851 -1,242
Capital Expenditures (CapEx)		 13 16 47 49 34 8.95 15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -94 94 -209 -184 -155 -71
Debt-free Net Working Capital (DFNWC)		 65 206 1,060 869 1,005 696 1,174
Net Working Capital (NWC)		 65 206 1,060 869 1,005 696 1,172
Net Nonoperating Expense (NNE)		 26 102 96 52 8.99 86 -189
Net Nonoperating Obligations (NNO)		 -87 -300 -966 -1,078 -1,190 -851 -1,242
Total Depreciation and Amortization (D&A)		 2.58 4.85 7.38 13 -0.21 8.83 6.34
Debt-free, Cash-free Net Working Capital to Revenue		 -146,900.00% -390,362.50% 181.17% -342.80% -48.82% -243.49% -50.62%
Debt-free Net Working Capital to Revenue		 363,366.67% 858,266.67% 2,043.77% 1,426.96% 266.20% 1,095.88% 840.45%
Net Working Capital to Revenue		 363,366.67% 858,266.67% 2,043.77% 1,426.96% 266.20% 1,095.88% 838.51%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 62.42M 64.23M 70.02M 77.15M 82.31M 98.91M
Adjusted Diluted Earnings per Share		 $0.00 ($4.19) ($5.77) ($4.13) ($1.72) ($4.58) ($0.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 62.42M 64.23M 70.02M 77.15M 82.31M 98.91M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.19) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 46.73M 68.73M 72.40M 81.66M 83.69M 101.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -53 -93 -275 -237 -124 -291 -269
Normalized NOPAT Margin		 -292,265.56% -387,216.67% -529.91% -388.93% -32.71% -457.98% -192.20%
Pre Tax Income Margin		 -435,144.44% -810,800.00% -714.91% -427.08% -34.73% -593.07% -57.24%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -41,181.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -30,525.06 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -46,382.22 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -35,726.28 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3.22% -1.06% -2.38% -0.07% -0.48% 0.00% 0.00%

Quarterly Metrics And Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 101,856,245.00 102,879,214.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 101,856,245.00 102,879,214.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.93 -1.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1,478.04% -69.39% -41.48% -17.01% -90.49% 0.81% -28.08% -32.03% 279.52% 324.87% -94.21%
EBITDA Growth		 470.48% -2.72% -8.27% 2.28% -165.04% -5.16% -7.69% -12.29% 80.96% 13.03% -12.51%
EBIT Growth		 393.81% -3.85% -11.06% -0.01% -176.67% -7.77% -8.92% -13.66% 78.73% 11.83% -14.11%
NOPAT Growth		 313.29% -5.26% -2.69% 1.63% -152.71% -14.55% -14.54% -19.07% 75.09% 10.12% -5.33%
Net Income Growth		 472.36% -2.29% -10.00% -0.60% -163.27% -10.74% -12.34% -16.61% 370.38% 12.93% -20.11%
EPS Growth		 453.70% 9.02% -2.78% 4.10% -157.07% -2.48% 9.91% 5.98% 332.11% 26.02% -18.00%
Operating Cash Flow Growth		 295.22% 9.17% 1.96% 1.85% -156.54% -4.15% 7.90% 7.54% -9.07% -23.71% 13.54%
Free Cash Flow Firm Growth		 -102.27% -15.15% -2.64% 19.48% -4,857.85% 11.62% 25.49% 34.65% 19.13% -35.65% -55.70%
Invested Capital Growth		 39.49% 39.23% 41.05% 43.16% 43.80% 46.53% 32.81% 19.83% 96.47% 157.51% 116.95%
Revenue Q/Q Growth		 1,739.07% -97.66% 58.87% 21.21% 110.72% -75.16% 13.33% 14.55% 1,076.62% -72.19% -98.46%
EBITDA Q/Q Growth		 225.24% -185.82% 5.47% -3.21% 16.64% -29.31% 3.20% -7.60% 84.36% -429.47% -26.10%
EBIT Q/Q Growth		 221.43% -183.66% 4.81% -3.42% 6.91% -17.60% 3.79% -7.89% 82.57% -383.59% -25.37%
NOPAT Q/Q Growth		 275.30% -154.86% -0.73% -1.53% 6.07% -19.24% -0.73% -5.54% 80.35% -330.21% -18.04%
Net Income Q/Q Growth		 248.61% -169.10% 7.72% -6.17% 6.53% -20.94% 6.39% -10.20% 316.71% -138.61% -30.07%
EPS Q/Q Growth		 256.56% -163.35% 8.26% -5.41% 6.84% -13.76% 19.35% -10.00% 330.00% -135.97% -29.67%
Operating Cash Flow Q/Q Growth		 250.44% -173.85% 16.78% -6.16% 13.34% -36.04% 26.41% -6.58% -2.22% -54.30% 48.57%
Free Cash Flow Firm Q/Q Growth		 98.52% -5,730.83% 4.78% 2.27% 8.63% -3.95% 19.73% 14.27% -13.06% -74.36% 7.86%
Invested Capital Q/Q Growth		 11.83% 13.18% 14.91% 12.74% 12.83% 17.39% -6.93% -4.11% 96.16% 1,445.63% -68.49%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 44.16% -1,506.92% -896.64% -763.49% -302.03% -1,571.99% -1,342.65% -1,261.13% -16.77% -319.20% -26,071.63%
Operating Margin		 42.02% -1,405.29% -891.06% -746.40% -332.71% -1,596.87% -1,419.22% -1,307.60% -15.29% -337.81% -25,827.14%
EBIT Margin		 41.78% -1,491.47% -893.66% -762.46% -336.85% -1,594.47% -1,353.52% -1,274.81% -18.88% -328.27% -26,657.14%
Profit (Net Income) Margin		 45.16% -1,331.57% -773.45% -677.47% -300.51% -1,462.78% -1,208.26% -1,162.38% 214.09% -297.18% -25,036.33%
Tax Burden Percent		 299.35% 0.00% 100.04% 100.00% 47.80% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 36.11% 0.00% 86.51% 88.85% 186.63% 91.74% 89.27% 91.18% -1,133.94% 90.53% 93.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -15.46% -16.09% -17.17% -18.29% -43.94% -38.04% -41.94% -47.19% -8.11% -5.77% -8.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -741.05% -2,198.39%
Operating Return on Assets (OROA)		 11.27% -399.90% -240.96% -216.57% -16.69% -71.73% -61.51% -57.21% -2.04% -36.53% -2,995.09%
Return on Assets (ROA)		 12.18% -357.02% -208.55% -192.43% -14.89% -65.80% -54.91% -52.16% 23.15% -33.07% -2,812.98%
Return on Common Equity (ROCE)		 -15.46% -16.09% -17.17% -18.29% -43.94% -38.04% -41.94% -47.19% -8.11% -5.77% -8.18%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -14.75% -16.74% -18.15% 0.00% -34.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 133 -73 -73 -75 -70 -84 -84 -89 -17 -75 -89
NOPAT Margin		 42.02% -983.70% -623.74% -522.48% -232.90% -1,117.81% -993.45% -915.32% -15.29% -236.47% -18,079.00%
Net Nonoperating Expense Percent (NNEP)		 0.88% -2.39% -1.69% -2.28% -1.99% -2.23% -1.69% -2.40% 25.01% -1.65% -3.10%
Return On Investment Capital (ROIC_SIMPLE)		 13.54% - - - -9.55% -7.43% -8.03% -9.18% -1.41% -5.92% -7.57%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 13.68% 360.65% 251.67% 185.82% 95.32% 374.03% 317.26% 275.73% 28.29% 108.48% 6,519.80%
R&D to Revenue		 44.30% 1,144.64% 739.39% 660.58% 337.39% 1,322.84% 1,201.96% 1,131.87% 87.00% 329.33% 19,407.35%
Operating Expenses to Revenue		 57.98% 1,505.29% 991.06% 846.40% 432.71% 1,697.23% 1,519.55% 1,407.60% 115.24% 437.81% 25,927.14%
Earnings before Interest and Taxes (EBIT)		 132 -111 -105 -109 -101 -119 -115 -124 -22 -104 -131
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 140 -112 -106 -109 -91 -117 -114 -122 -19 -101 -128
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.26 2.95 2.26 2.55 2.80 1.46 1.63 2.54 2.27 2.08 3.31
Price to Tangible Book Value (P/TBV)		 2.26 2.95 2.26 2.55 2.80 1.46 1.63 2.54 2.27 2.08 3.31
Price to Revenue (P/Rev)		 5.87 7.46 5.47 5.78 32.33 25.71 28.38 44.08 20.13 14.80 22.63
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.68 141.41
Enterprise Value to Revenue (EV/Rev)		 2.72 4.43 2.61 3.13 18.94 6.52 9.29 24.80 11.24 8.04 15.90
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.10
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.09
Financial Leverage		 -1.32 -1.29 -1.25 -1.24 -1.19 -1.14 -1.14 -1.14 -1.06 -1.02 -1.04
Leverage Ratio		 1.63 1.61 1.57 1.57 1.49 1.39 1.40 1.41 1.31 1.29 1.31
Compound Leverage Factor		 0.59 0.00 1.36 1.39 2.79 1.27 1.25 1.29 -14.87 1.17 1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12% 0.22% 8.12% 8.80%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12% 0.22% 0.21% 0.24%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.91% 8.57%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.88% 99.78% 91.88% 91.20%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.29 -0.28
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.42 3.34 3.10 2.83
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.28 -0.27
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.40 -0.39
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.29 4.63 4.26 3.97
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.39 -0.38
Altman Z-Score		 3.03 3.12 2.13 2.21 1.85 1.93 1.83 2.82 6.40 3.81 5.52
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.89 5.99 5.81 5.69 4.82 8.81 6.75 6.02 13.09 16.99 14.57
Quick Ratio		 5.79 5.85 5.69 5.57 4.67 8.62 6.61 5.89 12.85 16.25 14.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.26 -190 -181 -177 -161 -168 -135 -115 -131 -228 -210
Operating Cash Flow to CapEx		 3,763.53% -4,091.35% -4,232.99% -5,588.14% -2,571.21% -3,389.36% -2,437.82% -1,626.00% -2,230.56% -5,757.75% -2,738.03%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.27 0.27 0.27 0.28 0.05 0.05 0.05 0.04 0.11 0.11 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.14 2.97 2.87 2.90 0.54 0.55 0.53 0.50 1.29 1.56 1.51
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -209 -181 -154 -134 -117 -97 -104 -108 -4.14 56 18
Invested Capital Turnover		 -1.37 -1.51 -1.70 -1.89 -0.39 -0.46 -0.47 -0.46 -2.30 -7.97 -3.63
Increase / (Decrease) in Invested Capital		 136 117 107 102 91 84 51 27 113 152 121
Enterprise Value (EV)		 1,029 1,598 920 1,093 1,203 414 560 1,381 1,570 1,318 2,481
Market Capitalization		 2,219 2,693 1,929 2,019 2,054 1,634 1,710 2,455 2,813 2,427 3,531
Book Value per Share		 $12.04 $11.18 $10.38 $9.60 $8.86 $13.42 $10.41 $9.55 $12.20 $11.43 $10.38
Tangible Book Value per Share		 $12.04 $11.18 $10.38 $9.60 $8.86 $13.42 $10.41 $9.55 $12.20 $11.43 $10.38
Total Capital		 981 913 854 791 734 1,123 1,047 967 1,241 1,267 1,170
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.19 2.71 103 103
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100 100
Net Debt		 -1,190 -1,095 -1,008 -926 -851 -1,220 -1,150 -1,074 -1,242 -1,109 -1,050
Capital Expenditures (CapEx)		 3.59 2.44 1.96 1.58 2.97 3.07 3.14 5.01 3.73 2.23 2.41
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -184 -160 -156 -146 -155 -114 -149 -158 -71 -17 -52
Debt-free Net Working Capital (DFNWC)		 1,005 934 852 779 696 1,106 1,001 917 1,174 1,195 1,100
Net Working Capital (NWC)		 1,005 934 852 779 696 1,106 1,001 916 1,172 1,192 1,098
Net Nonoperating Expense (NNE)		 -9.94 26 18 22 20 26 18 24 -262 19 34
Net Nonoperating Obligations (NNO)		 -1,190 -1,095 -1,008 -926 -851 -1,220 -1,150 -1,074 -1,242 -1,109 -1,050
Total Depreciation and Amortization (D&A)		 7.53 -1.15 -0.35 -0.15 10 1.68 0.92 1.33 2.41 2.88 2.87
Debt-free, Cash-free Net Working Capital to Revenue		 -48.82% -44.35% -44.26% -41.89% -243.49% -179.12% -247.22% -283.28% -50.62% -10.10% -33.61%
Debt-free Net Working Capital to Revenue		 266.20% 258.93% 241.69% 222.88% 1,095.88% 1,739.70% 1,661.36% 1,646.61% 840.45% 728.67% 705.28%
Net Working Capital to Revenue		 266.20% 258.93% 241.69% 222.88% 1,095.88% 1,739.70% 1,661.36% 1,644.47% 838.51% 727.02% 703.50%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.24) ($1.00) ($1.10) $2.53 ($0.91) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M 104.33M
Adjusted Diluted Earnings per Share		 $1.91 ($1.21) ($1.11) ($1.17) ($1.09) ($1.24) ($1.00) ($1.10) $2.53 ($0.91) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 77.15M 81.70M 82.31M 82.41M 82.31M 87.98M 102.00M 102.57M 98.91M 103.26M 104.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 81.66M 82.31M 82.42M 82.81M 83.69M 100.56M 101.16M 101.47M 101.86M 102.88M 103.29M
Normalized Net Operating Profit after Tax (NOPAT)		 93 -73 -73 -75 -70 -83 -84 -89 -12 -75 -89
Normalized NOPAT Margin		 29.41% -983.70% -623.74% -522.48% -232.90% -1,117.55% -993.22% -915.32% -10.70% -236.47% -18,079.00%
Pre Tax Income Margin		 15.09% 0.00% -773.12% -677.47% -628.67% -1,462.78% -1,208.26% -1,162.38% 214.09% -297.18% -25,036.33%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.48% -0.42% -0.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Beam Therapeutics (NASDAQ:BEAM) remains well capitalized, but its financial profile continues to reflect a development-stage biotechnology company with significant operating losses and uneven revenue. The latest quarter showed improved cash burn and lower operating expenses, although revenue dropped sharply and the company remains dependent on its cash reserves, investment portfolio and financing activities.

  • Liquidity remains a major strength. As of June 30, 2026, Beam held $219.8 million in cash and equivalents plus $933.1 million in short-term investments, or approximately $1.15 billion in highly liquid assets. Against total liabilities of $318.9 million, this represents roughly $834 million of net liquidity.
  • Operating cash burn improved in the latest quarter. Net cash used in operating activities declined to $66.1 million in Q2 2026 from $128.5 million in Q1 2026 and $76.5 million in Q2 2025. This was the company’s lowest quarterly operating cash outflow among the reported 2025 and 2026 quarters.
  • Operating expenses declined sequentially. Total operating expenses fell to $127.0 million in Q2 2026 from $139.0 million in Q1 2026. Research and development spending declined to $95.1 million from $104.5 million, while selling, general and administrative expense fell to $31.9 million from $34.4 million.
  • Beam’s balance sheet has remained relatively resilient despite ongoing losses. Cash and short-term investments totaled approximately $1.15 billion in Q2 2026, compared with roughly $1.03 billion in Q3 2022. The company has funded several years of research spending while retaining substantial financial flexibility.
  • Revenue is highly volatile and appears to be collaboration- or milestone-driven. Quarterly revenue increased from $7.4 million in Q1 2024 to $114.1 million in Q4 2025, before falling to $31.7 million in Q1 2026 and just $490,000 in Q2 2026. Investors should not assume that the Q4 2025 revenue spike represents a recurring operating run rate.
  • Investment activity largely reflects portfolio management rather than operating growth. In Q2 2026, Beam purchased $180.9 million of investments and received $173.0 million from investment sales or maturities, producing a $9.9 million net investing cash outflow. Similar transactions have caused significant quarter-to-quarter swings in investing cash flow.
  • Beam continues to generate substantial net losses. Q2 2026 net loss was $122.7 million, or $1.18 per diluted share, compared with a $94.3 million loss, or $0.91 per share, in Q1 2026. The latest loss was also wider than the $102.1 million restated loss reported for Q2 2025, largely because revenue fell to $490,000.
  • The company remains far from operating profitability. Q2 2026 operating income was negative $126.6 million, despite gross profit of $490,000. Research and development spending alone was nearly 194 times quarterly revenue, underscoring Beam’s continued reliance on future clinical, regulatory and commercial milestones.
  • Debt has increased and interest expense is becoming more meaningful. Beam reported approximately $103.0 million of total debt at June 30, 2026, including $100.3 million of long-term debt. Interest expense was $7.5 million in Q2 2026, adding to the company’s quarterly loss and cash requirements.
  • Shareholder dilution has been a persistent trend. Weighted-average basic shares increased from 70.3 million in Q3 2022 to 104.3 million in Q2 2026. The company has used equity issuance, including a substantial $472.7 million issuance in Q1 2025, to support operations; future fundraising could further reduce existing investors’ ownership percentages.

Overall, Beam’s financial statements show a strong near-term liquidity position and some recent improvement in expense control and operating cash burn. However, the company’s core business has not yet become self-funding: revenue remains inconsistent, losses remain large, and research spending continues to consume cash. For investors, the most important future indicators will be the durability of collaboration revenue, progress toward clinical and commercial milestones, quarterly operating cash burn and whether additional equity or debt financing becomes necessary.

09/03/26 07:09 PM ETAI Generated. May Contain Errors.

Beam Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Beam Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Beam Therapeutics' net income appears to be on an upward trend, with a most recent value of -$79.99 million in 2025, rising from -$78.33 million in 2019. The previous period was -$376.74 million in 2024. See where experts think Beam Therapeutics is headed by visiting Beam Therapeutics' forecast page.

Beam Therapeutics' total operating income in 2025 was -$383.69 million, based on the following breakdown:
  • Total Gross Profit: $139.74 million
  • Total Operating Expenses: $523.44 million

Over the last 6 years, Beam Therapeutics' total revenue changed from $18 thousand in 2019 to $139.74 million in 2025, a change of 776,250.0%.

Beam Therapeutics' total liabilities were at $242.82 million at the end of 2025, a 34.4% decrease from 2024, and a 340.3% increase since 2019.

In the past 6 years, Beam Therapeutics' cash and equivalents has ranged from $37.22 million in 2019 to $559.99 million in 2021, and is currently $294.94 million as of their latest financial filing in 2025.

Over the last 6 years, Beam Therapeutics' book value per share changed from -31.04 in 2019 to 12.20 in 2025, a change of -139.3%.


Related Companies

Financial statements for NASDAQ:BEAM last updated on 8/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel